Source study found

Story checked

Oxaloacetate supplement may help reduce chemo brain in breast cancer survivors (opens in a new tab)

news-medical.net · 2026-10-21

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

2 supported
4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Oxaloacetate supplement may help reduce chemo brain in breast cancer survivors

news-medical.net · 2026-10-21

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

2 supported
4 not covered

Open claim evidence

The source study

Results From a Phase II Single-Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

JCO Oncology Advances · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe findings, published in JCO Oncology Advances, say breast cancer survivors with significant cancer-related cognitive impairment experienced improvements in memory, concentration and other cognitive symptoms after taking oxaloacetate for eight weeks, and also reported less fatigue and better physical functioning.View evidenceHide evidence

Why this verdict

The abstract profile supports pre-post improvements in perceived cognitive impairment, fatigue, and physical function after 8 weeks of oxaloacetate. However, the specific statement that memory and concentration improved is not available in the abstract-level profile, which does not report those specific symptom domains or subscale results. The main direction of the claim is consistent with the abstract, but the specific memory/concentration details are not verifiable at this evidence depth.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Study evidence

Total and mental fatigue improved after 8 weeks of oxaloacetate treatment in this cohort.P < .0001 (total fatigue and mental fatigue)

Claim 2 of 6Not coveredThe article says the researchers conducted a phase II clinical trial involving 18 women with early-stage breast cancer who were one to five years from diagnosis, most of whom had previously received chemotherapy and were receiving endocrine therapy.View evidenceHide evidence

As stated18 women

Why this verdict

The abstract profile supports that this was a single-arm phase II trial enrolling 18 early-stage breast cancer survivors with significant cognitive complaints. It states participants were 12 months to 5 years post–primary treatment, not specifically 1 to 5 years from diagnosis, and the abstract-level profile does not verify that all were women or that most had received chemotherapy and were receiving endocrine therapy.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Claim 3 of 6Not coveredOn average, scores on the study's primary measure of perceived cognitive impairment increased from 29.1 before treatment to 55.5 after eight weeks, moving the group from a range considered impaired to a range considered normal.View evidenceHide evidence

As stated29.1 to 55.5

Why this verdict

The abstract profile supports a large mean FACT-Cog PCI improvement of +26.4 points and movement from an impaired to normative range. But the exact pre- and post-treatment mean scores stated in the story, 29.1 and 55.5, are not directly provided in the supplied abstract-level profile, so the numerical magnitude as stated cannot be fully verified at this depth.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Claim 4 of 6Not coveredThe team is now preparing a randomized, placebo-controlled phase II trial in breast cancer survivors with cancer-related cognitive impairment expected to open in late 2026, and preclinical mouse studies are also underway.View evidenceHide evidence

As statedlate 2026

Why this verdict

The abstract-level profile says the findings support further evaluation in a randomized, placebo-controlled trial, but it does not verify that a new trial is being prepared, that it is expected to open in late 2026, or that preclinical mouse studies are underway. Those operational and preclinical details are not available at the supplied evidence depth.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Claim 5 of 6SupportedA new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that a nutritional supplement containing oxaloacetate may help improve cognitive function and reduce fatigue in some breast cancer survivors after treatment.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a preliminary, hedged claim that 8 weeks of oxaloacetate was associated with improved perceived cognitive impairment and fatigue-related outcomes in breast cancer survivors with CRCI. The story’s wording uses “may help” and “some,” which is appropriately cautious for a small single-arm phase II trial without a placebo group.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Study evidence

Total and mental fatigue improved after 8 weeks of oxaloacetate treatment in this cohort.P < .0001 (total fatigue and mental fatigue)

Claim 6 of 6SupportedThe researchers caution that the study was small and did not include a placebo or comparison group, so further research is needed to determine whether oxaloacetate was responsible for the improvements.View evidenceHide evidence

Why this verdict

The supplied profile explicitly lists the small sample size and single-arm uncontrolled design as key limitations, including lack of placebo/randomized comparator and limited causal attribution. It also states the findings are preliminary and support further randomized, placebo-controlled evaluation.

Study evidence

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)

Study evidence

Total and mental fatigue improved after 8 weeks of oxaloacetate treatment in this cohort.P < .0001 (total fatigue and mental fatigue)

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Safety and tolerability were a primary component of the paper: oxaloacetate was generally well tolerated, GI symptoms were the most common adverse events, two participants discontinued because of GI symptoms, and no serious adverse events were reported.
The story presentation focuses on cognitive and fatigue outcomes and limitations about efficacy attribution, but it does not reflect the paper’s material safety/tolerability findings or the GI-related discontinuations.
From Single-arm phase II trial
The 8-week treatment/follow-up period limits assessment of durability of benefits and longer-term safety.
The story states the intervention lasted eight weeks, but the supplied caveats do not identify short follow-up as a limitation for durability or long-term safety.
From Single-arm phase II trial (Simon's two-stage design with sequential monitoring); Single-arm phase II; Single-arm phase I
The abstract lacks detailed statistics for several secondary outcomes, especially objective neuropsychological testing, including confidence intervals, effect sizes, and exact test results.
The story mentions preliminary neuropsychological findings due to small sample size, but it does not reflect the additional abstract-level limitation that detailed neuropsychological test statistics and effect sizes are not provided.
From Single-arm phase II; Single-arm phase II trial with prospective pre–post neuropsychological assessment

5 things the story did carry across

The paper is a small, single-arm phase II interventional trial of oral oxaloacetate 500 mg twice daily for 8 weeks in early-stage breast cancer survivors with significant cancer-related cognitive complaints.
The primary endpoint was change in FACT-Cog Perceived Cognitive Impairment, with a reported mean improvement of +26.4 points and movement from impaired to normative range.
Secondary patient-reported outcomes included statistically significant improvements in total fatigue, mental fatigue, and physical function, with only a non-significant trend for insomnia.
Neuropsychological testing reportedly showed improvements in executive function and processing speed, but the abstract provides no test names, scores, effect sizes, or p-values for these objective outcomes.
Key limitations include no placebo or randomized comparator, small sample size, and limited causal inference from single-arm pre-post changes.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate safety and preliminary efficacy of oral anhydrous enol-oxaloacetate (500 mg twice daily for 8 weeks) for improving cancer-related cognitive impairment (CRCI) cognitive complaints in early-stage breast cancer survivors, with primary endpoint change in FACT-Cog PCI.Single-arm phase II trial (Simon's two-stage design with sequential monitoring)Expand

In plain English

Single-arm phase II trial of oral anhydrous enol-oxaloacetate (500 mg twice daily for 8 weeks) in early-stage breast cancer survivors with self-reported moderate-to-severe cancer-related cognitive impairment; primary outcome was change in perceived cognitive impairment (FACT-Cog PCI). Eighteen participants were enrolled (16 completers). Treatment was associated with a large, clinically and statistically significant mean improvement in FACT-Cog PCI (+26.4 points, P < .0001) and improvements in fatigue and physical function; oxaloacetate was generally well tolerated with gastrointestinal adverse events the most common reason for discontinuation (2 participants), and no serious adverse events reported.

Key findings

Treatment was associated with a clinically and statistically significant improvement in perceived cognitive impairment as measured by FACT-Cog PCI.+26.4 points (mean change)
Statistically significant improvements were observed in total fatigue and mental fatigue following treatment.

What this piece can’t prove

Single-arm, uncontrolled study design limits ability to attribute observed changes to the intervention (no placebo/randomized comparator).
Small sample size (18 enrolled, 16 completers) reduces precision and generalizability.
Short intervention and follow-up period (8 weeks) limit assessment of durability of effects and longer-term safety.
Abstract lacks detailed neuropsychological test statistics, effect sizes, and confidence intervals for reported outcomes.

2human in vivoAssess secondary patient-reported outcomes (fatigue, insomnia, psychological symptoms, health-related quality of life/physical function) following 8 weeks of oxaloacetate in the same cohort.Single-arm phase IIExpand

In plain English

In a single-arm phase II trial of oral oxaloacetate 500 mg twice daily for 8 weeks in breast cancer survivors with cancer-related cognitive impairment, pre-post analyses of secondary patient-reported outcomes showed statistically significant improvements in total and mental fatigue and in physical function, and a non-significant trend toward improved insomnia. Psychological symptom outcomes were listed as a secondary domain but not reported in the abstract. The cohort included 18 enrolled participants with 16 completers; two participants discontinued treatment due to gastrointestinal adverse events.

Key findings

Total and mental fatigue improved after 8 weeks of oxaloacetate treatment in this cohort.P < .0001 (total fatigue and mental fatigue)
Physical function (a domain of health-related quality of life) improved following treatment.P = .0003

What this piece can’t prove

Single-arm, uncontrolled design limits ability to attribute observed changes to the intervention versus placebo effect, regression to the mean, or natural recovery.
Small sample size (18 enrolled, 16 completers) reduces precision and generalizability.
Short treatment and follow-up duration (8 weeks) limits assessment of durability of effects.
Abstract does not report details on instruments used for secondary PROs or effect size magnitudes beyond p-values.
Two participants discontinued due to gastrointestinal adverse events, which may affect tolerability estimates.

3human in vivoAssess objective neuropsychological test performance changes (eg, executive function, processing speed) after the intervention in the same cohort.Single-arm phase II trial with prospective pre–post neuropsychological assessmentExpand

In plain English

In this single-arm phase II trial of oral oxaloacetate (500 mg twice daily for 8 weeks) in breast cancer survivors with cancer-related cognitive impairment, secondary neuropsychological testing reportedly showed improvements in executive function and processing speed; 18 participants were enrolled and 16 completed the intervention. The abstract does not report test names, effect sizes, or detailed statistics for these objective cognitive outcomes.

Key findings

Neuropsychological testing showed improvements in executive function and processing speed after 8 weeks of oxaloacetate in this single-arm trial.

What this piece can’t prove

Abstract provides no details on the neuropsychological test battery, exact outcome measures, timing of assessments, numerical results, effect sizes, or statistical tests for the objective cognitive outcomes.
Because neuropsychological testing was a secondary outcome, the abstract does not indicate whether analyses were adjusted for multiplicity or describe prespecified endpoints for these measures.

2 further details could not be confirmed from the summary.

4human in vivoCharacterize safety/tolerability and adverse events (including GI symptoms and discontinuations; absence of serious AEs) during oxaloacetate treatment.Single-arm phase II trialExpand

In plain English

In this single-arm phase II trial of oral anhydrous enol-oxaloacetate (500 mg twice daily for 8 weeks) in breast cancer survivors with cancer-related cognitive impairment, oxaloacetate was reported to be generally well tolerated. Gastrointestinal (GI) symptoms were the most common adverse events and led to treatment discontinuation in two participants; there were no serious adverse events reported among study participants.

Key findings

Oxaloacetate was generally well tolerated in this cohort.
Gastrointestinal symptoms were the most common adverse events and led to treatment discontinuation in two participants; no serious adverse events were observed.

What this piece can’t prove

Small sample size (n=18) limits precision of safety estimates.
Single-arm, uncontrolled design prevents comparison to background symptom rates or placebo-attributable adverse event rates.
Short intervention duration (8 weeks) limits detection of less frequent or longer-latency adverse events.
Abstract lacks detailed AE reporting (frequency table, severity grading, formal causality assessments).

Finally, the search trail

Method layer